+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors for cytomegalovirus disease in high risk renal allograft recipients under oral ganciclovir prophylaxis



Risk factors for cytomegalovirus disease in high risk renal allograft recipients under oral ganciclovir prophylaxis



Nephrology Dialysis Transplantation 16(6): A219




(PDF emailed within 1 workday: $29.90)

Accession: 035672670

Download citation: RISBibTeXText


Related references

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70(8): 1174-1180, 2000

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 77(2): 305-308, 2004

Prophylactic oral ganciclovir prevents cytomegalovirus disease in high-risk renal transplant recipients. Journal of the American Society of Nephrology 7(9): 1941, 1996

A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Transplantation Proceedings 37(7): 3053-3055, 2005

Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Kidney and Blood Pressure Research 28(4): 218-225, 2005

Ganciclovir in cytomegalovirus prophylaxis in high-risk pediatric renal transplant recipients. Transplantation Proceedings 25(4): 2577, 1993

Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transplant Infectious Disease 11(2): 106-111, 2008

Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. American Journal of Transplantation 3(6): 731-735, 2003

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 66(12): 1682-1688, 1999

Valacyclovir For Cytomegalovirus Prophylaxis Reduces The Risk Of Acute Renal Allograft Rejection: A Randomized Comparison With Oral Ganciclovir And Deferred Therapy. Transplantation Journal 78: 483-484, 2004

Failure of ganciclovir prophylaxis of primary cytomegalovirus disease in immunologic high-risk recipients. Transplantation Proceedings 30(4): 1314-1315, 1998

Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. Journal of the American Society of Nephrology 7(2): 325-330, 1996

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrobial Agents and ChemoTherapy 35(5): 938-943, 1991

Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients. Transplantation Proceedings 27(1): 961-963, 1995

Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction. American Journal of Transplantation 2(7): 671-673, 2002